Why ICU Patients Waste Muscle and How GH Peptides Could Fix It | Research

The takeaway

Critical illness disrupts the GH axis in two phases — initial GH surge with IGF-1 resistance, then suppressed GH secretion — and GH secretagogues combined with TRH can reverse the late-phase suppression.

GH injections doubled mortality
Direct GH replacement was harmful in ICU patients, but GH secretagogues that restore pulsatile patterns may be safe — delivery method matters

What the researchers found

Critical illness causes biphasic GH axis disruption; GH secretagogues + TRH restore physiological pulsatile GH secretion more safely than direct GH replacement, which increased mortality in a large clinical trial.

Why it matters

A landmark trial showed high-dose GH injections doubled mortality in ICU patients. GH secretagogues may achieve the anabolic benefits without the danger, by restoring natural GH patterns rather than flooding the body with exogenous GH.

How the study worked

Review of neuroendocrine changes during critical illness, clinical trial data on GH treatment (including the negative outcomes), and the rationale for GH secretagogue-based approaches.

What this study cannot tell us

The safety advantage of GH secretagogues over GH injections in ICU was hypothesized but not proven in head-to-head mortality trials at time of review.

How to read the evidence

Moderate evidence from a review incorporating landmark clinical trial data and mechanistic rationale for GH secretagogue approaches.

When this study was published

Published in 1999. The finding that GH injections are harmful but GH secretagogues may be beneficial in critical illness continues to guide ICU endocrine research.

The bigger picture

The difference between harmful GH replacement and potentially beneficial GH secretagogues illustrates a crucial pharmacological principle: how a hormone is delivered matters as much as how much. Pulsatile GH (via secretagogues) may be safe while continuous GH (via injections) is dangerous.

Questions still open

Can GHRP-2/TRH reduce ICU mortality and length of stay?
What makes pulsatile GH safer than continuous GH?
Should all ICU patients receive GH secretagogue assessment?

Common questions

Why did growth hormone injections harm ICU patients?

High-dose continuous GH overwhelmed already stressed systems, increasing fluid retention, blood sugar, and immune dysfunction. The body needs GH in natural pulses, not constant flooding — GH secretagogues restore pulses.

Could GH peptides help ICU patients?

Unlike GH injections, GH secretagogues restore the body's own pulsatile GH pattern. This approach showed promise in restoring hormones without the dangers of direct GH, but larger trials are needed.

Read the original research

Growth hormone secretagogues in critical illness.

Hormone research, 51 Suppl 3, 21-8

View on PubMed ↗

Citation

Van den Berghe, G. (1999). Growth hormone secretagogues in critical illness.. Hormone research, 51 Suppl 3, 21-8.